The apoptotic potential of TRAIL has shown to improve via combinatory treatment with etoposide, doxorubicin or paclitaxel mediated upregulation of both DR4 (TRAILI) and DR5 (TRAILII) expression in numerous breast cancer cells types in vitro, as well as in tumorigenic mice [169]. This evidence concerns the gene TNFSF10 and breast carcinoma.